These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31106957)

  • 21. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays.
    Ingerslev J; Jankowski MA; Weston SB; Charles LA;
    J Thromb Haemost; 2004 Apr; 2(4):623-8. PubMed ID: 15102018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.
    Hillarp A; Bowyer A; Ezban M; Persson P; Kitchen S
    Haemophilia; 2017 May; 23(3):458-465. PubMed ID: 28198071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory.
    Cauchie M; Toelen J; Peerlinck K; Jacquemin M
    Haemophilia; 2013 May; 19(3):e133-8. PubMed ID: 23374099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring standard and extended half-life products in hemophilia: Assay discrepancies for factor VIII and IX in pre- and postinfusion samples.
    Augustsson C; Norström E; Andersson NG; Zetterberg E; Astermark J; Strandberg K
    Res Pract Thromb Haemost; 2020 Oct; 4(7):1114-1120. PubMed ID: 33134777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variability in combinations of APTT reagent and substrate plasma for a one-stage clotting assay to measure factor VIII products.
    Suzuki A; Suzuki N; Kanematsu T; Okamoto S; Suzuki N; Tamura S; Kikuchi R; Katsumi A; Kojima T; Matsushita T
    Int J Lab Hematol; 2024 Aug; 46(4):705-713. PubMed ID: 38426662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
    Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
    Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PK-guided personalized prophylaxis with Nuwiq
    Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
    Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Factor VIII assays in treated hemophilia A patients].
    Lasne D; Pouplard C; Nougier C; Eschwege V; Le Cam Duchez V; Proulle V; Smahi M; Harzallah I; Voisin S; Toulon P; Sobas F; Galinat H; Flaujac C; Ternisien C; Jeanpierre E;
    Ann Biol Clin (Paris); 2019 Feb; 77(1):53-65. PubMed ID: 30799298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves.
    Van den Bossche D; Toelen J; Schoeters J; Van Horenbeeck I; Vanlinthout I; Debasse M; Peerlinck K; Jacquemin M
    Haemophilia; 2019 Jan; 25(1):e19-e26. PubMed ID: 30589148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq
    Lissitchkov T; Hampton K; von Depka M; Hay C; Rangarajan S; Tuddenham E; Holstein K; Huth-Kühne A; Pabinger I; Knaub S; Bichler J; Oldenburg J
    Haemophilia; 2016 Mar; 22(2):225-231. PubMed ID: 26315974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simoctocog alfa (Nuwiq
    Klukowska A; Sidonio RF; Young G; Mancuso ME; Álvarez-Román MT; Bhatnagar N; Jansen M; Knaub S
    Ther Adv Hematol; 2024; 15():20406207241245511. PubMed ID: 38737006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.
    Kessler C; Oldenburg J; Ettingshausen CE; Tiede A; Khair K; Négrier C; Klamroth R
    Haemophilia; 2015 Jan; 21 Suppl 1():1-12. PubMed ID: 25472812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A.
    Suzuki A; Suzuki N; Kanematsu T; Okamoto S; Tamura S; Kikuchi R; Katsumi A; Kiyoi H; Kojima T; Matsushita T
    Int J Lab Hematol; 2021 Feb; 43(1):131-138. PubMed ID: 32915508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.
    Sandberg H; Kannicht C; Stenlund P; Dadaian M; Oswaldsson U; Cordula C; Walter O
    Thromb Res; 2012 Nov; 130(5):808-17. PubMed ID: 23010293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq
    Klukowska A; Szczepański T; Vdovin V; Knaub S; Jansen M; Liesner R
    Haemophilia; 2016 Mar; 22(2):232-239. PubMed ID: 26370328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
    Mathias M; Abraham A; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jiménez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pollio B; Sigaud M; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Eur J Haematol; 2023 Oct; 111(4):544-552. PubMed ID: 37439123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance evaluation of Revohem
    Suzuki A; Suzuki N; Kanematsu T; Shinohara S; Arai N; Kikuchi R; Matsushita T
    Int J Lab Hematol; 2019 Oct; 41(5):664-670. PubMed ID: 31271527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional characteristics of N8, a new recombinant FVIII.
    Christiansen ML; Balling KW; Persson E; Hilden I; Bagger-Sørensen A; Sørensen BB; Viuff D; Segel S; Klausen NK; Ezban M; Lethagen S; Steenstrup TD; Kjalke M
    Haemophilia; 2010 Nov; 16(6):878-87. PubMed ID: 20546031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution.
    Caron C; Dautzenberg MD; Delahousse B; Droulle C; Pouzol P; Dubanchet A; Rothschild C
    Haemophilia; 2002 Sep; 8(5):639-43. PubMed ID: 12199672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.